Abbott Laboratories
Abbott Laboratories Reports Fourth-Quarter and Full-Year 2023 Financial Results
Summary
On January 24, 2024, Abbott Laboratories announced its financial results for the fourth quarter and full year 2023. Fourth-quarter reported sales increased by 1.5 percent, while full-year sales decreased by 8.1 percent primarily due to the decline in COVID-19 testing-related sales. GAAP diluted EPS for the full year was $3.26, and adjusted diluted EPS was $4.44. Abbott's segments showed varied performance with Medical Devices and Nutrition segments performing well despite declines in Diagnostics due to reduced COVID-19 testing demand. The company also provided its financial outlook for 2024.
Profitelligence Alerts
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement